This is unsurprising as following RxPONDER the ASCO guidelines were updated to recommend the use of Oncotype DX testing to guide decision making regarding adjuvant chemotherapy use among postmenopausal women with ER-positive, HER2-negative, N1 breast cancer. The gene discussed is ERBB2; the disease is breast cancer.